Disparity in market prices for hepatitis C virus direct-acting drugs.

www.thelancet.com/lancetgh Vol 3 November 2015 e676 gross national income (figure). In high-income countries, the price per bottle of sofosbuvir ranged from $14 000 (Spain) to $20 590 (Switzerland). Prices for daclatasvir ranged from $1128 (South Korea) to $14 899 (Germany); those of simeprevir from $9166 (Spain) to $14 865 (Australia); those of ledipasvir-sofosbuvir from $12 604 (USA) to $24 890 (Germany); and those of the 2D regimen from $15 344 (UK) to $20 215 (Switzerland). In low-income and middle-income countries, prices were generally substantially lower than in highincome countries. However, there Disparity in market prices for hepatitis C virus direct-acting drugs